Skip To Content

Study ID: Merck MK-3475-177 Keynote 177 Colorectal

Title:

A Phase III Study of Pembrolizumab (MK3475) vs Chemotherapy in Microsatellite Instability- High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma

Location:
Sioux Falls Region
Principal Investigator:
Jonathan Bleeker, MD
Disease:
Colorectal
Stage:
Phase III
Status:
Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.